Patents Examined by Stacy B. Chen
-
Patent number: 12037359Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 22, SEQ ID NO: 51 or SEQ ID NO: 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO: 4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.Type: GrantFiled: December 8, 2020Date of Patent: July 16, 2024Assignee: Cytiva BioProcess R&D ABInventors: Gustav José Rodrigo, Tomas Bjorkman, Mats Ander
-
Patent number: 12024555Abstract: The present disclosure is directed to antibodies binding to and neutralizing West Nile virus and methods for use thereof.Type: GrantFiled: March 26, 2019Date of Patent: July 2, 2024Assignee: VANDERBILT UNIVERSITYInventor: James E. Crowe, Jr.
-
Patent number: 12023375Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.Type: GrantFiled: April 4, 2022Date of Patent: July 2, 2024Assignee: University of WashingtonInventors: Michael J. Gale, Jr., Gretja Schnell, Yueh-Ming Loo
-
Patent number: 12005115Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.Type: GrantFiled: July 7, 2020Date of Patent: June 11, 2024Assignee: The United States of America as Represented By The Secretary of the Department of Health and Human ServicesInventors: Masaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu
-
Patent number: 11998597Abstract: Compositions including a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.Type: GrantFiled: January 10, 2022Date of Patent: June 4, 2024Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Dirk André Emmy Roymans
-
Patent number: 11998581Abstract: The present invention is directed to a recombinant herpesvirus comprising a heterologous polypeptide ligand capable of binding to a target molecule and fused to or inserted into glycoprotein B at specific sites. The herpesvirus may comprise more than one ligand, and the additional ligand(s) may be comprised by a modified glycoprotein D and/or modified glycoprotein H. This allows the herpesvirus to target a cell for therapeutic purposes, and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gB, a polypeptide comprising the gB, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.Type: GrantFiled: April 30, 2021Date of Patent: June 4, 2024Assignee: ALMA MATER STUDIORUM—UNIVERSITÀ DI BOLOGNAInventors: Maria Gabriella Campadelli, Biljana Petrovic
-
Patent number: 11992524Abstract: Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.Type: GrantFiled: October 24, 2022Date of Patent: May 28, 2024Assignee: Genvivo, Inc.Inventors: Jacqueline Fischer-Lougheed, Bradford H. Steele, Cecilia Roh, Robert G. Johnson
-
Patent number: 11975062Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.Type: GrantFiled: November 30, 2018Date of Patent: May 7, 2024Assignee: Takeda Vaccines, Inc.Inventors: Jill A. Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Asae Shintani, Holli Giebler, James Gifford, Mark Lyons, Sushma Kommareddy, Tatsuki Satou
-
Patent number: 11964011Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: March 6, 2023Date of Patent: April 23, 2024Assignee: CureVac SEInventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
-
Patent number: 11964012Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: March 6, 2023Date of Patent: April 23, 2024Assignee: CureVac SEInventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
-
Patent number: 11958884Abstract: Methods and compositions are provided that can be used to modify the assembly activating protein (AAP)-dependence of an adeno-associated virus (AAV).Type: GrantFiled: May 21, 2021Date of Patent: April 16, 2024Assignees: Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.Inventors: Luk H. Vandenberghe, Anna Claire Maurer
-
Patent number: 11944681Abstract: The invention is directed to HIV-1 neutralizing antibodies and methods for their uses.Type: GrantFiled: June 24, 2021Date of Patent: April 2, 2024Assignees: Duke University, University of MarylandInventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody, LaTonya Williams, Kevin J. Wiehe, Gilad Adi Ofek
-
Patent number: 11931406Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.Type: GrantFiled: December 12, 2018Date of Patent: March 19, 2024Assignees: CureVac SE, Sanofi PasteurInventors: Patrick Baumhof, Wolfgang Grosse, Edith Jasny, Thomas Kramps, Daniel Voss, Julia Dannenmaier, Valérie Lecouturier, Yves Girerd-Chambaz
-
Patent number: 11931399Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: December 12, 2022Date of Patent: March 19, 2024Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
-
Patent number: 11926861Abstract: The invention describes a method for determining how to stimulate, monitor and/or inhibit virus production in whole blood culture. The invention relates to a test kit for performing the method and to the use of a suitable blood sampling system. The system can be used to determine how to activate or target latently HIV-infected cells, for clinical management of HIV treatments and for personalized therapeutic strategies.Type: GrantFiled: February 3, 2020Date of Patent: March 12, 2024Inventor: Heidi Kay
-
Patent number: 11911456Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: April 7, 2021Date of Patent: February 27, 2024Assignee: Vactech OyInventors: Heikki Hyöty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 11913074Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: March 17, 2023Date of Patent: February 27, 2024Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 11912757Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.Type: GrantFiled: June 1, 2021Date of Patent: February 27, 2024Assignee: HUMABS BIOMED SAInventor: Davide Corti
-
Patent number: 11897939Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.Type: GrantFiled: October 9, 2020Date of Patent: February 13, 2024Assignees: The University of North Carolina at Chapel Hill, The Johns Hopkins UniversityInventors: Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kenetta Nunn, Durai Babu Subramani, Richard Cone, Bing Yang, Justin Mccallen
-
Patent number: 11883486Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: June 1, 2023Date of Patent: January 30, 2024Assignee: CureVac SEInventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch